The historical rank and industry rank for Xenetic Biosciences's FCF Margin % or its related term are showing as below:
XBIO'
s FCF Margin % Range Over the Past 10 Years
Min: -37641.18 Med: -293.47 Max: 19.58
Current: -57.08
During the past 13 years, the highest FCF Margin % of Xenetic Biosciences was 19.58%. The lowest was -37641.18%. And the median was -293.47%.
XBIO's FCF Margin % is ranked better than 53.08% of 959
companies
in the Biotechnology industry
Industry Median: -84.65
vs XBIO: -57.08
Xenetic Biosciences FCF Margin % Related Terms
Xenetic Biosciences FCF Margin % Historical Data
* Premium members only.
The historical data trend for Xenetic Biosciences's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Xenetic Biosciences's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xenetic Biosciences FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Xenetic Biosciences's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Xenetic Biosciences's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xenetic Biosciences (XBIO) has a FCF Margin % of -66.42% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Xenetic Biosciences and its competitors. According to the industry distribution chart, Xenetic Biosciences ranks #450 out of 959 companies in the Biotechnology industry, placing it in the top 46.9%.
Is Xenetic Biosciences' FCF Margin % too high?
Xenetic Biosciences' current FCF Margin % is -66.42%. Based on the distribution chart, Xenetic Biosciences ranks #450 out of 959 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Xenetic Biosciences has a GF Score™ of 83/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Xenetic Biosciences' FCF Margin % compare to PCSA and SILO?
According to the Biotechnology industry distribution chart, Xenetic Biosciences ranks #450 out of 959 companies for FCF Margin %. This puts Xenetic Biosciences in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Xenetic Biosciences and its competitors. Xenetic Biosciences's current FCF Margin % is -66.42%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xenetic Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Xenetic Biosciences (XBIO) is currently considered Possible Value Trap. The stock's GF Value™ is $4.18, compared to a current price of $2.95 — trading 29.5% below its estimated fair value. The current FCF Margin % is -66.42%. Xenetic Biosciences' overall GF Score™ is 83/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Xenetic Biosciences (XBIO), the current FCF Margin % is -66.42% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xenetic Biosciences (XBIO) Overvalued in 2026?
Based on GuruFocus' analysis, Xenetic Biosciences stock appears to be undervalued.
The current stock price of $2.95 is trading 29.5% below its estimated GF Value™ of $4.18.
GuruFocus considers Xenetic Biosciences to be Possible Value Trap.
Key valuation signals for XBIO:
FCF Margin %: -66.42%
GF Value™: $4.18 vs. price of $2.95 (29.5% below fair value)
No single metric tells the full story. See the XBIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xenetic Biosciences Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. Additionally, Xenetic is leveraging PolyXen™, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen™ has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and expects to earn royalty payments under this agreement.
83GF Score
Get the complete analysis for XBIO
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XBIO has been successfully added to your 
